Sign-up-button1







Categorie: Emerging Markets
Submitted 7 months ago by No_photo_15x12 Dreamdamodar contact me
Lupin has announced that its subsidiary, Lupin Pharmaceuticals Inc has launched Suprax 400 mg tablets (Cefixime USP) in the US. This line extension, further extends the brand franchise of Lupins flagship anti-intective Suprax. Suprax 400 mg tablets will help Lupin to further increase its share of the $450 million antibiotic market for the treatment of urinary tract infections. It will also extend the use of Suprax to the patient population of children of the age of 12 yrs and above. Suprax 400 mg tablets will be promoted by a 60 strong specialty pediatric sales force. Lupin is also evaluating additional options of reaching out to other specialty doctors- Its efforts will he supplemented by innovative promotional campaigns. The Suprax brand basket now includes, Suprax (Cefixime for oral suspension 100 mg / 5 ml and 200 mg / 5ml and Suprax 400 mg tablets (Cefixime USP). More...

0 comments ↓




Please Login or Register to comment

India economy emerging markets Pakistan reliance BHEL power fund banks Asia IT mortgage housing bank siemens US GOOG telecommunications educational baidu bidu Pharmaceutical Biotech Investing in Sin Obesity Diabetes Novo Nordisk Reliance Infratel IPO FIIs Stock Investing Trading Sensex Mutual Funds Deciem in AUM emerging market Funds Tractors Autos vehicles Review Financial Millat limited expansion Software company IT company UAE Petrobras PBR Brazil Oil wireless technology AMX VIP VSL Private Sector ICICI bank Vs Rest

More Tags